These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 22495652)
1. Supervised Bayesian latent class models for high-dimensional data. Desantis SM; Houseman EA; Coull BA; Nutt CL; Betensky RA Stat Med; 2012 Jun; 31(13):1342-60. PubMed ID: 22495652 [TBL] [Abstract][Full Text] [Related]
2. High CHI3L1 expression is associated with glioma patient survival. Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858 [TBL] [Abstract][Full Text] [Related]
3. Protein and mRNA levels of YKL-40 in high-grade glioma. Kazakova MH; Staneva DN; Koev IG; Staikov DG; Mateva N; Timonov PT; Miloshev GA; Sarafian VS Folia Biol (Praha); 2014; 60(6):261-7. PubMed ID: 25629266 [TBL] [Abstract][Full Text] [Related]
4. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900 [TBL] [Abstract][Full Text] [Related]
5. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701 [TBL] [Abstract][Full Text] [Related]
6. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Tanwar MK; Gilbert MR; Holland EC Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854 [TBL] [Abstract][Full Text] [Related]
8. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594 [TBL] [Abstract][Full Text] [Related]
9. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Horbinski C; Wang G; Wiley CA Int J Clin Exp Pathol; 2010 Jan; 3(3):226-37. PubMed ID: 20224722 [TBL] [Abstract][Full Text] [Related]
10. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Ku BM; Lee YK; Ryu J; Jeong JY; Choi J; Eun KM; Shin HY; Kim DG; Hwang EM; Yoo JC; Park JY; Roh GS; Kim HJ; Cho GJ; Choi WS; Paek SH; Kang SS Int J Cancer; 2011 Mar; 128(6):1316-26. PubMed ID: 20506295 [TBL] [Abstract][Full Text] [Related]
11. Association between YKL-40 and adult primary astrocytoma. Zhang W; Kawanishi M; Miyake K; Kagawa M; Kawai N; Murao K; Nishiyama A; Fei Z; Zhang X; Tamiya T Cancer; 2010 Jun; 116(11):2688-97. PubMed ID: 20499402 [TBL] [Abstract][Full Text] [Related]
12. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas. Vachher M; Arora K; Burman A; Kumar B J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121 [TBL] [Abstract][Full Text] [Related]
14. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675 [TBL] [Abstract][Full Text] [Related]
15. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
16. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study. Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173 [TBL] [Abstract][Full Text] [Related]
17. Identifying influential observations in Bayesian models by using Markov chain Monte Carlo. Jackson D; White IR; Carpenter J Stat Med; 2012 May; 31(11-12):1238-48. PubMed ID: 21905065 [TBL] [Abstract][Full Text] [Related]
18. Order selection for heterogeneous semiparametric hidden Markov models. Zou Y; Song X; Zhao Q Stat Med; 2024 Jun; 43(13):2501-2526. PubMed ID: 38616718 [TBL] [Abstract][Full Text] [Related]
19. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Ma X; Yoshimoto K; Guan Y; Hata N; Mizoguchi M; Sagata N; Murata H; Kuga D; Amano T; Nakamizo A; Sasaki T Neuro Oncol; 2012 Sep; 14(9):1153-62. PubMed ID: 22844109 [TBL] [Abstract][Full Text] [Related]
20. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]